Tesamorelin
A synthetic GHRH analog studied, and approved in a specific HIV lipodystrophy indication, for reducing visceral fat via endogenous GH release.
What Tesamorelin is
Tesamorelin is a stabilized analog of growth hormone-releasing hormone that stimulates pituitary GH secretion, raising IGF-1 and influencing body composition. It is distinctive among research-discussed peptides because a specific formulation received FDA approval to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Phase 3 programs led by Falutz and colleagues demonstrated meaningful reductions in visceral adipose tissue over 26 weeks with daily subcutaneous administration, with extension data informing durability and metabolic secondary endpoints. Separate work evaluated liver fat and other cardiometabolic markers in HIV populations with central fat accumulation. These papers are the correct primary anchors for dosage education.
Outside labeled use, tesamorelin appears in broader body-composition research conversations. Educational content should keep approved indication, trial doses, and off-label speculation clearly separated, and should use research-use-only language for non-labeled contexts. This page summarizes documented ranges for reference by research professionals.
Tesamorelin has been studied in human trials, which is not true of most compounds in this library. The figures below come from that work.
How it works
Tesamorelin binds pituitary GHRH receptors, amplifying physiologic GH pulsatility rather than supplying exogenous growth hormone directly. Increased GH acts on hepatic and peripheral tissues to raise IGF-1, promote lipolysis in visceral fat depots, and support lean-mass signals. Preferential VAT reduction with relative subcutaneous fat sparing was a recurring theme in HIV lipodystrophy trials. Downstream metabolic effects on triglycerides and hepatic fat have been examined as secondary physiology.
Who works with it, and what they are measuring
Infectious-disease and endocrinology investigators working on HIV metabolic complications are the core clinical-research audience. Body-composition and NAFLD-oriented teams analyze VAT and liver-fat imaging endpoints. Peptide educators reference tesamorelin as a fully specified GHRH-analog case study with published phase 3 dose regimens.
What the research examines
These are areas of active investigation. Listing a topic here does not mean an effect is established, approved, or proven in humans.
How it appears in the literature
Figures as they appear in the source literature. Context matters more than the number.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Pivotal HIV lipodystrophy clinical trials (original 2 mg daily subcutaneous regimen) | 2 mg | once daily | subcutaneous |
| Research discussions of GH-axis body-composition protocols referencing the clinical dose anchor | 1 mg – 2 mg | daily | subcutaneous |
Handling & storage
Approved product labeling specifies controlled storage and reconstitution steps; research lyophilizates should remain refrigerated per COA. Use diluent only as directed, refrigerate reconstituted solution, and discard after the labeled period.
Notes on combined research
Clinical trials evaluate tesamorelin on optimized antiretroviral and lifestyle backgrounds, not stacked with other GH secretagogues. Combining GHRH analogs with GHRPs/ghrelin mimetics is sometimes hypothesized to amplify GH release but introduces confounding and safety-monitoring complexity. Research designs usually isolate the GHRH analog.
Tesamorelin questions
Pivotal HIV-associated lipodystrophy trials used 2 mg subcutaneously once daily for the original formulation. That is the best-documented human dose anchor in the peer-reviewed literature. Newer branded presentations may list different nominal milligram strengths that are designed to be exposure-matched, always read the specific label or trial protocol.
Follow the product's reconstitution instructions when using approved kits. For research lyophilized vials, choose a diluent volume that delivers 2 mg in a convenient syringe volume (for example, 2 mg in 1 mL yields 2 mg/mL). Do not assume multi-peptide blend volumes apply.
Daily dosing, not weekly, is the regimen used in the major VAT-reduction trials. Educational charts should show mcg or mg per day and note morning abdominal subcutaneous administration patterns described in clinical materials.
A simple chart maps 2 mg daily to syringe units at your concentration. If reconstituted to 2 mg/mL, 1.0 mL = 2 mg. IGF-1 monitoring schedules from clinical practice are separate from the injection-volume chart and belong in protocol documents.
Primary VAT imaging endpoints in phase 3 work were assessed at 26 weeks, with extension observations to 52 weeks in some analyses. Benefits on visceral fat were treatment-dependent in follow-up discussions. Timelines refer to trial populations with HIV-associated central fat accumulation.
As a peptide GHRH analog, plasma persistence is short; pharmacodynamic effects run through GH secretion and IGF-1 elevation lasting longer than the parent peptide's plasma spike. Cite clinical pharmacology references for numeric half-life values.
Evidence-based protocols study it as a single GH-axis agent. Stacking with CJC-1295, ipamorelin, or exogenous GH overlaps pathways and is not how pivotal trials were run. Research clarity favors monotherapy plus defined background care.
Read the research yourself
Every link below was verified against the NCBI PubMed database. We do not cite what we cannot point you to.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.PubMed
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.PubMed
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.PubMed
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.PubMed